Metropolitan Life Insurance CO Edgewise Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.25 - $19.97 $4,292 - $9,266	464 Added 17.73%	3,081 $56,000
Q3 2023 Nov 14, 2023	BUY	$5.73 - $7.69 $3,008 - $4,037	525 Added 25.1%	2,617 $14,000
Q1 2023 May 15, 2023	SELL	$6.66 - $11.33 $4,741 - $8,066	-712 Reduced 25.39%	2,092 $13,000
Q4 2022 Jun 14, 2023	BUY	$7.58 - $11.08 $5,396 - $7,888	712 Added 34.03%	2,804 $25.1 Million
Q3 2022 Jun 14, 2023	BUY	$8.08 - $13.58 $5,752 - $9,668	712 Added 34.03%	2,804 $27.6 Million
Q2 2022 Jun 20, 2023	BUY	$5.67 - $9.87 $4,037 - $7,027	712 Added 34.03%	2,804 $22,000
Q1 2022 Jun 20, 2023	BUY	$9.1 - $18.97 $6,479 - $13,506	712 Added 34.03%	2,804 $27,000
Q1 2022 Mar 30, 2023	SELL	$9.1 - $18.97 $75,784 - $157,982	-8,328 Reduced 74.81%	2,804 $27,000
Q1 2022 May 12, 2022	SELL	$9.1 - $18.97 $75,784 - $157,982	-8,328 Reduced 74.81%	2,804 $27,000
Q4 2021 Jun 21, 2023	BUY	$14.41 - $22.41 $130,266 - $202,586	9,040 Added 432.12%	11,132 $170,000
Q4 2021 Mar 30, 2023	BUY	$14.41 - $22.41 $120,006 - $186,630	8,328 Added 297.0%	11,132 $170,000
Q4 2021 Feb 15, 2022	BUY	$14.41 - $22.41 $160,412 - $249,468	11,132 New	11,132 $170,000

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.